Innovative Medical's Stock Experiences Abnormal Volatility Amid Heightened Market Interest in Its Brain-Computer Interface Subsidiary

China Data Network  Innovative HealthcareZhejiang Shanxiahu Pearl Group Co., Ltd. (Stock Code: 002173) announced that the closing price of its stock had risen cumulatively by more than 20% over three consecutive trading days on January 8, 9, and 12, 2026, constituting an abnormal trading fluctuation. After verification, the company confirmed that there is no need to correct previously disclosed information, and there have been no significant changes in recent production, operations, or internal and external environments. The controlling shareholder and actual controller have no significant matters that should have been disclosed but were not, and they did not buy or sell the company’s stock during the period of abnormal fluctuations.

The announcement specifically mentioned that the market has recently paid high attention to the company's brain-computer interface business. The main body of this business is the holding subsidiary, Cereblink (Hangzhou) Technology Co., Ltd., which was included in the consolidated financial statements in August 2025. Its products are mainly used for motor function rehabilitation training and assistance for patients with cerebrovascular diseases such as stroke and hemiplegia. In terms of core products, "Cereblink AC5" was launched for sale in October 2025, generating revenue of 114,000 yuan that year; another product, "Cereblink AM5," has completed multi-center clinical trials but did not generate revenue in 2025. Financial data shows that Cereblink incurred operating losses of 6.6017 million yuan and 8.6641 million yuan in 2023 and 2024, respectively.

The company's board of directors stated that, apart from the disclosed information, there is no other significant information that should be disclosed but has not been, and reminded investors to pay attention to the information on designated media and be aware of investment risks.